Trial Profile
Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma: A Phase II, Multi-center, Open-label Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2019
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 02 Jan 2015 New trial record